闻晓光博士，国家级特聘专家，越洋医药创始人、董事长兼CEO。

闻博士是国家卫健委新药创制重大专项的项目负责人，也曾是国家科技部973课题分课题（释药技术及其机理研究）负责人。

闻博士是中国药学会制剂专业委员会委员、中国药学会工业药剂学专业委员会委员、中国颗粒协会理事、北大医学部优秀校友。

闻博士回国前曾在葛兰素史克（GSK）和辉瑞（Pfizer）参与多个缓控释新药开发和上市；回国后曾在药明康德担任制剂部执行总监，曾担任科技部制剂新技术国家重点实验室主任。

闻博士参与编著《Oral Controlled Release Formulation Design and Drug Delivery：Theory to Practice》(John Wiley & Sons,Inc 出版)一书，以及科技导报关于缓控释新药的特邀综述《新型制剂的研发与创新》一文。闻博士拥有15项在中美欧日获得授权的缓控释技术及产品发明专利，同时拥有3项实用新型专利。

Dr. Xiaoguang (Gilbert) Wen

Dr. Gilbert Wen is the founder of Overseas Pharmaceuticals Ltd, a specialty pharmaceutical company focusing on developing modified release platform technologies and applying these proprietary technologies to develop NDA products in collaboration with transnational pharmaceutical companies. Among many honors and recognitions, Dr. Wen is a distinguished expert of the Thousand Talent Program (entrepreneurial category) in China and a committee member of Pharmaceutics in Chinese Pharmaceutical Association. In addition, Dr. Wen is a recipient of Distinguished Alumni of Medical School of Beijing University. He holds 15 granted patents and authored a chapter in the book “Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice.”

Dr. Wen has previously worked as a formulation scientist in the Product Line Extension division at GSK and in the R&D headquarter for Consumer Health Care Division at Pfizer (Wyeth). After returning to China, he became the head of the State Key Laboratory of Ministry of Science and Technology for Advanced and Novel Controlled Release Technologies and also served as an executive director at Wuxi Apptech.